latanoprostene bunod
Selected indexed studies
- Latanoprostene Bunod. (, 2006) [PMID:30000019]
- Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (Med Gas Res, 2025) [PMID:39829161]
- Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis. (J Clin Med, 2022) [PMID:35893417]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Latanoprostene Bunod. (2006) pubmed
- Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. (2025) pubmed
- Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis. (2022) pubmed
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. (2020) pubmed
- Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. (2018) pubmed
- Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. (2019) pubmed
- Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. (2017) pubmed
- Newer advances in medical management of glaucoma. (2022) pubmed
- Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy. (2018) pubmed
- Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. (2025) pubmed